A Study of ZT002 in Healthy Participants

PHASE1UnknownINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

December 14, 2023

Study Completion Date

April 14, 2024

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

ZT002

"Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"

OTHER

Placebo

"Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings"

Trial Locations (1)

Unknown

RECRUITING

Q-Pharm Pty Limited, Herston

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

collaborator

Beijing QL Biopharmaceutical Co.,Ltd

INDUSTRY

lead

QL Biopharmaceutical Australia Pty Ltd

INDUSTRY